XML 61 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
ACQUISITIONS - Pro forma impact of business combinations (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2015
Pro forma of consolidated results of operations    
Revenues $ 2,805.0 $ 5,076.2
Net loss attributable to Valeant Pharmaceuticals International, Inc. $ (30.1) $ (299.9)
Loss per share attributable to Valeant Pharmaceuticals International, Inc.:    
Basic (in usd per share) $ (0.09) $ (0.87)
Diluted (in usd per share) $ (0.09) $ (0.87)